Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | methionine aminopeptidase MapB | 0.0546 | 0.1704 | 0.5 |
Trypanosoma cruzi | metallo- peptidase, Clan MG, Family M24 | 0.0862 | 0.4038 | 1 |
Trypanosoma brucei | metallo- peptidase, Clan MG, Family M24 | 0.0862 | 0.4038 | 1 |
Mycobacterium leprae | PROBABLE METHIONINE AMINOPEPTIDASE MAPA (MAP) (PEPTIDASE M) (MetAP) | 0.0546 | 0.1704 | 0.5 |
Toxoplasma gondii | methionine aminopeptidase | 0.0546 | 0.1704 | 0.422 |
Trypanosoma cruzi | metallo- peptidase, Clan MG, Family M24 | 0.0862 | 0.4038 | 1 |
Trypanosoma brucei | methionine aminopeptidase, putative | 0.0862 | 0.4038 | 1 |
Plasmodium falciparum | methionine aminopeptidase 1b, putative | 0.0862 | 0.4038 | 1 |
Leishmania major | methionine aminopeptidase, putative,metallo-peptidase, Clan MG, Family M24 | 0.0862 | 0.4038 | 1 |
Toxoplasma gondii | methionine aminopeptidase, type i, putative | 0.0546 | 0.1704 | 0.422 |
Loa Loa (eye worm) | methionine aminopeptidase type I | 0.0862 | 0.4038 | 0.5 |
Plasmodium falciparum | methionine aminopeptidase 1a, putative | 0.0546 | 0.1704 | 0.422 |
Chlamydia trachomatis | methionine aminopeptidase | 0.0546 | 0.1704 | 0.5 |
Plasmodium vivax | methionine aminopeptidase 1a, putative | 0.0546 | 0.1704 | 0.422 |
Treponema pallidum | methionine aminopeptidase (map) | 0.0546 | 0.1704 | 0.5 |
Mycobacterium tuberculosis | Methionine aminopeptidase MapB (map) (peptidase M) | 0.0546 | 0.1704 | 0.5 |
Mycobacterium leprae | PROBABLE METHIONINE AMINOPEPTIDASE MAPB (MAP) (PEPTIDASE M) | 0.0546 | 0.1704 | 0.5 |
Mycobacterium ulcerans | methionine aminopeptidase | 0.0546 | 0.1704 | 0.5 |
Trypanosoma brucei | methionine aminopeptidase, type I, putative | 0.0862 | 0.4038 | 1 |
Toxoplasma gondii | methionine aminopeptidase | 0.0862 | 0.4038 | 1 |
Plasmodium vivax | methionine aminopeptidase 1b, putative | 0.0862 | 0.4038 | 1 |
Echinococcus multilocularis | methionyl aminopeptidase 1 (M24 family) | 0.0862 | 0.4038 | 0.2813 |
Echinococcus multilocularis | microtubule associated protein 2 | 0.1668 | 1 | 1 |
Brugia malayi | Methionine aminopeptidase protein type I | 0.0862 | 0.4038 | 0.5 |
Schistosoma mansoni | microtubule-associated protein tau | 0.1668 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | methionine aminopeptidase | 0.0546 | 0.1704 | 0.5 |
Mycobacterium tuberculosis | Methionine aminopeptidase MapA (map) (peptidase M) (MetAP) | 0.0546 | 0.1704 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.8913 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 25.1189 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (binding) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.